PDE

(redirected from Phosphodiesterases)
Also found in: Dictionary, Medical, Encyclopedia.
AcronymDefinition
PDEPennsylvania Department of Education
PDEPartial Differential Equation
PDEPhosphodiesterases
PDEPlug-In Development Environment
PDEPulse Detonation Engine
PDEParamount Digital Entertainment
PDEPlataforma en Defensa de l'Ebre (Catalan: Platform for the Defence of the River Ebre)
PDEPersonal Digital Entertainment
PDEPrescription Drug Event
PDEProduct Data Exchange
PDEPresent-Day English
PDEPosition Determining Entity
PDEPhoton Detection Efficiency
PDEPlataforma en Defensa del Ebro (Spanish: Platform for the Defence of the River Ebre)
PDEProject Development Engineer
PDEPortable Electronic Device
PDEProduct Design Engineer
PDEPyridoxine-Dependent Epilepsy
PDEPrimary Designated Engineer
PDEProcess Development Engineer
PDEPrimark Decision Economics
PDEProduction Estimate
PDEPotential Daily Exposure
PDEPhiladelphia Drug Exchange
PDEProjected Operational Environment
PDEPropagation Delay Estimation
PDEPre-Emphasis/De-Emphasis
PDEPreliminary Determination of Epicenter(s) (USGS)
PDEPaddle Drive Electronics
PDEProject/Program Director, Electronics
PDEPreliminary Data Element
PDEPermission Display Engine
PDEPredictive Density Estimation
PDEProcessing Development Environment (software)
PDEPersonal Development Education
PDEProfessional Development Event
PDEPurely Domestic Enterprise (finance)
PDEPrimary Developmental Education (US Air Force)
PDEPlanning, Decision, and Execution
References in periodicals archive ?
The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.
Leading Organisations in Phosphodiesterases Research Include:
lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3
The central focus of the 'Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact' report is an assessment of the therapeutic and market potential of phosphodiesterase inhibitors.
This two-day conference emphasizes the importance of Phosphodiesterases in genetic studies.
Phosphodiesterases are a family of enzymes that metabolize the intracellular second messengers cyclic AMP (cAMP) and cyclic GMP.
LifeSpan's DrugTarget Database is the industry's largest resource for proprietary human protein localization data for drug targets in eight important gene families, including G protein-coupled receptors (GPCRs), nuclear hormone receptors (NHRs), kinases, ion channels, phosphatases, proteases, phosphodiesterases, and transporters.
Aptosyn(R) is a cGMP phosphodiesterases (cGMP-PDEs) inhibitor which leads to the activation of the intracellular signaling protein, Protein Kinase G (PKG), and subsequent stimulation of apoptosis through the c-Jun kinase pathway.
a privately held drug discovery company, today presented research results from the company's drug discovery program involving the discovery and development of drug candidates targeting phosphodiesterase (PDE) enzymes at the Strategic Research Institute's "Phosphodiesterases in Disease" Conference in Princeton, New Jersey.
Full browser ?